Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louis M Aledort

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Seminars in Thrombosis and Hemostasis|March 18, 2003
Orthopedic outcome studies and cost issuesLouis M Aledort
The New England Journal of Medicine|February 20, 2020
Emicizumab in Hemophilia A. ReplyLouis M Aledort
Expert Review of Hematology|November 19, 2010
Expert Review of Hematology: addressing the needs of a broad research fieldLouis M Aledort
Current Hematology Reports|February 22, 2005
Platelet bleeding disorders and approach to their managementLouis M Aledort
Thrombosis and Haemostasis|October 4, 2002
Can costs of hemophilia products be curtailed? Not as we do business today!Louis M Aledort
The New England Journal of Medicine|November 5, 2010
Off-label use of recombinant activated factor VII--safe or not safe?Louis M Aledort
The Journal of Thoracic and Cardiovascular Surgery|December 23, 2003
Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe?Louis M Aledort
The New England Journal of Medicine|November 7, 2019
Deaths Associated with Emicizumab in Patients with Hemophilia ALouis M Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 13, 2019
The ongoing imperative for immune tolerance induction in inhibitor managementLouis M Aledort
Current Hematology Reports|February 18, 2004
Do we need a better test? Can thrombin generation be useful?Louis M Aledort
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Seminars in Thrombosis and Hemostasis|March 18, 2003
Orthopedic outcome studies and cost issuesLouis M Aledort
The New England Journal of Medicine|February 20, 2020
Emicizumab in Hemophilia A. ReplyLouis M Aledort
Expert Review of Hematology|November 19, 2010
Expert Review of Hematology: addressing the needs of a broad research fieldLouis M Aledort
Current Hematology Reports|February 22, 2005
Platelet bleeding disorders and approach to their managementLouis M Aledort
Thrombosis and Haemostasis|October 4, 2002
Can costs of hemophilia products be curtailed? Not as we do business today!Louis M Aledort
The New England Journal of Medicine|November 5, 2010
Off-label use of recombinant activated factor VII--safe or not safe?Louis M Aledort
The Journal of Thoracic and Cardiovascular Surgery|December 23, 2003
Activated prothrombin complex concentrates and recombinant factor VIIa in the bleeding patient: are they appropriate and safe?Louis M Aledort
The New England Journal of Medicine|November 7, 2019
Deaths Associated with Emicizumab in Patients with Hemophilia ALouis M Aledort
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 13, 2019
The ongoing imperative for immune tolerance induction in inhibitor managementLouis M Aledort
Current Hematology Reports|February 18, 2004
Do we need a better test? Can thrombin generation be useful?Louis M Aledort
Pageof 4